Latest News
- Am 22. Mai 2025 geben Plusultra pharma GmbH und InfectoPharm Arzneimittel und Consilium GmbH bekannt, künftig bei der Vermarktung des Arzneimittels Hyftor® 2 mg/g Gel (Wirkstoff: Sirolimus) in Deutschland zusammenzuarbeiten.
- Am 29. April 2025 geben Plusultra pharma GmbH und InfectoPharm Arzneimittel und Consilium GmbH die
Unterzeichnung eines verbindlichen Term Sheets für die exklusive Vermarktung des Produkts Hyftor®
2 mg/g Gel in Frankreich und Italien bekannt. InfectoPharm wird das Produkt in diesen beiden Ländern
bewerben und vertreiben und damit den Markt für Hyftor® 2mg/g Gel erweitern. - On October 11, 2024, the price negotiations with the GKV-SV regarding Hyftor® 2 mg/g gel were successfully concluded. Hyftor will be available and reimbursable for your patients on the German market as a medication with orphan drug status.
- Since November 1, Hyftor® 2 mg/g gel has been available on the German healthcare market as a prescription-only medicine. The distribution partner in Germany is PHOENIX Pharma-Einkauf GmbH, Hanau. Hyftor® 2 mg/g Gel can therefore be ordered from pharmacies and fully stocked wholesalers.
For further information on the product see: Hyftor | European Medicines Agency (europa.eu)
Contribute to Society by Providing Critical but Neglected Pharmaceuticals and Medical Devices.
About Plusultra pharma
As a research and development-based pharmaceutical company, we develop pharmaceuticals for unmet needs, such as orphan drugs. Before delivering new products, we always consider the needs of our customers.
Pipeline
Plusultra pharma, as a group of Nobelpharma, has earnestly addressed the launch of medicines that other companies do not pursue, in order to fulfil the needs of society.
Our contact information:
Phone number: +49 (0) 211 900 667 – 99
E-Mail: pup-info@plusultra-pharma.de
Bezüglich Hyftor:
Bestellungen über Ihren regionalen Großhandel bei:
PHOENIX Pharma-Einkauf GmbH Lippestrasse 9a, 63452 Hanau, Deutschland
Tel.: +49 (0) 6181 304107-12
Fax +49 (0) 911 2479009119
E-Mail: imex-logistik@phoenixgroup.eu
Contact Us
“Critical but neglected – That is precisely why it must be created.”
Plusultra pharma GmbH and Plusultra pharma UK Ltd. were established in Duesseldorf, Germany, and Oxford, United Kingdom, respectively in 2020, as overseas subsidiaries in Europa regions of Nobelpharma Group. The headquarter of the group, Nobelpharma was founded in 2003 in Tokyo, Japan, to fulfill our mission of “Contributing to Society by Providing Critical but Neglected Pharmaceuticals and Medical Devices“ that other companies do not pursue. We have since obtained approvals for the manufacturing and sale of new drugs in numbers on par with large pharmaceutical companies, and we have been providing these drugs to patients. We take much pride in the unique corporate philosophy that has made this possible.